Clinical and laboratory characteristics at diagnosis and outcomes
| . | PETHEMA LPA99 . | PETHEMA/ HOVON LPA2005 . | GIMEMA AIDA2000 . | ICAPL . |
|---|---|---|---|---|
| N | 561 | 402 | 453 | 806 |
| Age, y, median (range) | 40 (2-83) | 42 (3-83) | 40.9 (18.0-61.0) | 35 (15-74) |
| ECOG PS score ≥2, n (%) | 138 (27) | 67 (20) | n.a | 262 (32.5) |
| Relapse risk group, n (%) | ||||
| Low | 107 (19) | 84 (21) | 116 (25.6) | 87 (10.8) |
| Int/high | 453 (81) | 318 (79) | 337 (74.4) | 716 (89.2) |
| WBC count, ×109/L, median (range) | 2.2 (0.2-460) | 3.0 (0.3-126) | 2.3 (0.3-770.0) | 4.1 (0.1-537.2) |
| Platelet count, ×109/L, median (range) | 22 (1-207) | 23 (1-235) | 24.0 (0.5-264.0) | 20.4 (0.6-185) |
| bcr3 PML/RARA isoform, n (%) | 204 (40) | 117 (45) | 128 (36.4%) | 280 (36.5) |
| Fibrinogen, mg/dL, n (%) | ||||
| ≤170 | 280 (54) | 176 (48) | n.a. | 343 (56.3) |
| >170 | 240 (46) | 193 (52) | n.a. | 266 (43.7) |
| Albumin, g/dL, n (%) | ||||
| ≤3.5 | 107 (24) | 66 (20) | n.a. | 114 (22.7) |
| >3.5 | 335 (76) | 267 (80) | n.a. | 388 (77.3) |
| Main treatment outcomes | ||||
| CR rate, n (%) | 511 (91) | 372 (92) | 420 (94.4) | 687 (85.4) |
| Death in induction rate, n (%) | 50 (8.9) | 29 (7.4) | 25 (5.6) | 117 (14.6) |
| OS, % | 83% at 4 y | 88% at 4 y | 87.4% at 6 y | 81% at 4 y |
| DFS, % | 84% at 4 y | 90% at 4 y | 85.6% at 6 y | 80% at 4 y |
| CIR, % | 11% at 4 y | 9% at 4 y | 10.7% at 6 y | 15% at 4 y |
| . | PETHEMA LPA99 . | PETHEMA/ HOVON LPA2005 . | GIMEMA AIDA2000 . | ICAPL . |
|---|---|---|---|---|
| N | 561 | 402 | 453 | 806 |
| Age, y, median (range) | 40 (2-83) | 42 (3-83) | 40.9 (18.0-61.0) | 35 (15-74) |
| ECOG PS score ≥2, n (%) | 138 (27) | 67 (20) | n.a | 262 (32.5) |
| Relapse risk group, n (%) | ||||
| Low | 107 (19) | 84 (21) | 116 (25.6) | 87 (10.8) |
| Int/high | 453 (81) | 318 (79) | 337 (74.4) | 716 (89.2) |
| WBC count, ×109/L, median (range) | 2.2 (0.2-460) | 3.0 (0.3-126) | 2.3 (0.3-770.0) | 4.1 (0.1-537.2) |
| Platelet count, ×109/L, median (range) | 22 (1-207) | 23 (1-235) | 24.0 (0.5-264.0) | 20.4 (0.6-185) |
| bcr3 PML/RARA isoform, n (%) | 204 (40) | 117 (45) | 128 (36.4%) | 280 (36.5) |
| Fibrinogen, mg/dL, n (%) | ||||
| ≤170 | 280 (54) | 176 (48) | n.a. | 343 (56.3) |
| >170 | 240 (46) | 193 (52) | n.a. | 266 (43.7) |
| Albumin, g/dL, n (%) | ||||
| ≤3.5 | 107 (24) | 66 (20) | n.a. | 114 (22.7) |
| >3.5 | 335 (76) | 267 (80) | n.a. | 388 (77.3) |
| Main treatment outcomes | ||||
| CR rate, n (%) | 511 (91) | 372 (92) | 420 (94.4) | 687 (85.4) |
| Death in induction rate, n (%) | 50 (8.9) | 29 (7.4) | 25 (5.6) | 117 (14.6) |
| OS, % | 83% at 4 y | 88% at 4 y | 87.4% at 6 y | 81% at 4 y |
| DFS, % | 84% at 4 y | 90% at 4 y | 85.6% at 6 y | 80% at 4 y |
| CIR, % | 11% at 4 y | 9% at 4 y | 10.7% at 6 y | 15% at 4 y |
AIDA, all-trans retinoic and idarubicin; GIMEMA, Gruppo Italiano Malattie EMatologiche dell'Adulto; Int, intermediate; n.a., not available; PS, performance status.